MDCalc

Memorial Sloan-Kettering Cancer Center (MSKCC/Motzer) Score for Metastatic Renal Cell Carcinoma (RCC)

Predicts survival based on clinical and laboratory data in metastatic RCC patients.

  • Use baseline factors at the start date of the current line of systemic therapy, except for the “time of diagnosis to systemic therapy” criterion, which is always relative to first-line therapy.

  • Always correct calcium concentration for low albumin before scoring.

Time from diagnosis to systemic treatment <1 year
Measured ~1 month after stopping anticoagulation
Hemoglobin < Lower Limit of Normal
  • Men (Normal): 13.5-17.5 g/dL
  • Women (Normal): 12.0-15.5 g/dL
Calcium >10mg/dL (>2.5 mmol/L)
LDH > 1.5x Upper Limit of Normal
Normal: 140 U/L
Performance status <80% (Karnofsky)

Result:

Please fill out required fields.
Management

The score is currently not used for treatment decision-making. The IMDC Risk Model, which was originally based on the MSKCC/Motzer score, is currently used in treatment decision-making for metastatic RCC (NCCN Guidelines 2019).

Critical Actions

Can only be applied to patients with metastatic RCC that receive systemic therapy.

Have feedback about this calculator?